Trial Profile
An Exploratory Phase I, Randomised, Open-Label, 3-Way Cross-over, Single Centre Study In Healthy Subjects To Investigate The Pharmacokinetics Of An Inhaled Formulation Of Fluticasone Propionate And Salmeterol (As Xinafoate) 250/25 ?g Delivered Via Two Different Inhalation Devices, Compared To A Reference Product
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Acronyms PSX2005-07
- Sponsors Niox
- 02 Jan 2018 New trial record